Study on the application effect of Budesonide combined with pulmonary surfactant intratracheal administration in the prevention of bronchepul-monary dysplasia in premature infants
Study on the application effect of Budesonide combined with pulmonary surfactant intratracheal administration in the prevention of bronchepul-monary dysplasia in premature infants
Objective To explore the application effect of Budesonide combined with pulmonary surfactant(PS)intratra-cheal administration in the prevention of bronchepulmonary dysplasia(BPD)in premature infants.Methods A total of 40 high-risk infants with BPD admitted to the Department of Neonatology,Ping Xiang Maternity and Child Care from Jan-uary 2022 to August 2023 were selected as the research objects.They were divided into observation group and control group by random number table method,with 20 cases in each group.The control group was treated with exogenous PS alone,and the observation group was treated with Budesonide on the basis of the control group.The number of PS repeated application,nasal catheter oxygen inhalation time,invasive ventilation time,non-invasive ventilation time,ventilator use time,total oxy-gen therapy time,incidence and severity of BPD,total hospitalization time,hospitalization cost,and incidence of various complications were compared between the two groups.Results The total incidence of BPD in the observation group was lower than that in the control group,and the difference was statistically significant(P＜0.05).The repeated application times of PS in the observation group was less than that in the conventional group,and the invasive ventilation time,non-invasive ventilation time,ventilator use time and total oxygen therapy time were shorter than those in the control group,with statisti-cally significant differences(P＜0.05).There was no significant difference in the time of oxygen inhalation through nasal catheter between the two groups(P＞0.05).The hospitalization cost of the observation group was lower than that of the con-trol group,and the difference was statistically significant(P＜0.05).There was no significant difference in the total length of hospital stay between the two groups(P＞0.05).There was no significant difference in the incidence of complications be-tween the two groups(P＞0.05).Conclusion Compared with the use of PS alone,the combination of Budesonide and PS in the treatment of high-risk premature infants with BPD can reduce the frequency of repeated use of PS,lower respiratory pa-rameters,shorten respiratory support time,and lower the incidence and severity of BPD.Moreover,it does not increase the incidence of glucocorticoid related complications,which is worthy of clinical promotion and use.
维普
万方数据